KR102564361B1 - Composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5 - Google Patents

Abstract

Disclosed herein is a composition for preventing hair loss or promoting hair growth containing ginsenoside F5. The composition promotes the secretion of placenta growth factor in dermal papilla cells, thereby improving the depth of pores and the thickness of the scalp, so it can be used to improve, treat or prevent hair loss.

Description

Composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5

Disclosed herein is a composition for preventing hair loss or promoting hair growth containing ginsenoside F5.

Although hair is not important for maintaining life, it is a measure of health and an important part of the body that determines the appearance from a cosmetic point of view. Therefore, for ordinary people with a lot of hair, daily hair loss is taken for granted as a natural physical activity, but for those who are experiencing hair loss due to aging or various other causes, depression, shame, social isolation, etc. have a serious impact on the mental aspect and furthermore on the quality of life. is receiving

Research on hair growth, hair loss, and prevention of hair loss has been conducted for a long time, but the mechanism of hair growth and hair loss has not yet been accurately identified. Alternatively, molecular biological research is actively being conducted, and great efforts are being made to develop drugs that can treat hair loss and promote hair growth.

Currently, drugs that promote hair growth that have been approved by the Food and Drug Administration (FDA) include Minoxidil, Finasteride, and Propecia. However, these drugs have side effects such as short duration of drug effect, loss of libido, risk of pregnant women, worse condition than before drug administration or hormonal imbalance when drug administration is stopped, so development of new treatments is necessary.

KR10-2003-7001736 A

In one aspect, an object of the present invention is to provide a composition for preventing or improving hair loss, or promoting hair growth.

In another aspect, an object of the present invention is to promote the secretion of placental growth factor in dermal papilla cells by using ginsenoside F5.

In one aspect, the present invention provides a composition for preventing or improving hair loss, or promoting hair growth, comprising ginsenoside F5 as an active ingredient.

In one aspect, a composition containing ginsenoside F5, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof as an active ingredient promotes the secretion of placenta growth factor in dermal papilla cells, , Since it can improve the depth of the pores and the thickness of the scalp, it can have the effect of preventing hair loss or promoting hair growth. In addition, since it is harmless to the human body, it has the advantage of being able to treat hair loss without side effects.

1 is a diagram confirming the expression level of placental growth factors after treatment with ginsenoside F5 (con: control group, EGC: epigallocatechin treatment group, EGCG: epigallocatechin gallate treatment group, GT stem cells: tea leaf stem cell extract treatment group, F1: ginsenoside F1 treatment group, F2: ginsenoside F2 treatment group, F5: ginsenoside F5 treatment group, k: ginsenoside compound K treatment group).

The amount of placental growth factor secreted from dermal papilla cells decreases with repeated subcultures of all udder cells. On the other hand, when the scalp is treated with placental growth factor (PIGF), the hair shaft, pore depth, and scalp thickness increase to a degree similar to that of minoxidil, which is widely used as a hair growth agent (Yoon SY et al. al., Journal of Dermatological Science. 2014). On the other hand, the present inventors confirmed that the amount of placental growth factor secreted by the dermal papilla cells increased when ginsenoside F5 was treated with the dermal papilla cells, thereby completing the present invention.

Hereinafter, the present invention will be described in detail.

In one aspect, the present invention provides a composition for preventing or improving hair loss or promoting hair growth, comprising ginsenoside F5, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof as an active ingredient. am.

The ginsenoside F5 may be, for example, a material having the following structural formula:

.

As used herein, “isomer” refers in particular to optical isomers (e.g., essentially pure enantiomers, essentially pure diastereomers, or mixtures thereof) as well as conformational isomers ( Includes conformation isomers (i.e. isomers that differ only in the angle of one or more chemical bonds), position isomers (particularly tautomers) or geometric isomers (e.g. cis-trans isomers) do.

As used herein, "essentially pure", e.g., when used in reference to enantiomers or diastereomers, contains at least about 90%, specifically at least about 95%, of a specific compound exemplified by the enantiomer or diastereomer; more specifically about 97% or more or about 98% or more, even more specifically about 99% or more, even more specifically about 99.5% or more (w/w) present.

As used herein, “pharmaceutically acceptable” means approval by the government or a regulatory body equivalent thereto that can be used in animals, more specifically in humans, by avoiding significant toxic effects when used in normal medical dosages. Received or approved, or listed in a pharmacopeia or otherwise recognized in a general pharmacopeia.

As used herein, "pharmaceutically acceptable salt" means a salt according to one aspect of the present invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. These salts are (1) formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-Toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2,2,2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert - acid addition salts formed with organic acids such as butylacetic acid, laurylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid; or (2) a salt formed when an acidic proton present in the parent compound is substituted.

In the present specification, "prodrug" means a drug whose physical and chemical properties are controlled by chemically changing a drug, and does not show physiological activity by itself, but is originally produced by chemical or enzymatic action in the body after administration. can be turned into a drug to exert its medicinal effect.

In the present specification, "hydrate" means a compound in which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.

As used herein, "solvate" refers to a higher order compound formed between solute molecules or ions and solvent molecules or ions.

In the present specification, "hair loss" may refer to a state in which there is no hair in an area where hair should normally exist, and may mean, for example, that hair on the scalp is lost.

In addition, in the present specification, “promotion of hair growth” may mean promoting the growth of existing hair as well as promoting new hair growth.

In the above aspect, the composition may promote the secretion of growth factors in scalp cells.

In the present specification, "scalp cells" may include all types of cells constituting the epidermis, dermis, and subcutaneous tissue of the scalp.

In one embodiment, the scalp cells may be human follicle dermal papilla cells. The dermal papilla cells are separated from the dermal cell layer and refer to cells existing at the base of the hair follicle. It is known that dermal papilla cells are responsible for hair growth and hair follicle cycle control by supplying oxygen and nutrients to the cells constituting the hair follicle.

In the above aspect, the growth factor may be placental growth factor (PIGF). Placental growth factor is a protein encoded by the PGF gene and is a type of vascular endothelial growth factor (VEGF).

In the above aspect, the ginsenoside F5 may be derived from ginseng. The ginseng may be a root, stem, flower, fruit or leaf part of ginseng. Ginsenoside F5 is especially abundant in hydroponic ginseng. For example, ginsenoside F5 can be obtained by extracting hydroponic ginseng.

In the present specification, "ginseng" may mean a perennial plant of the Araliaceae family, and may include leaves, roots, tissue cultured ginseng, fruits, and seeds. The height is 50 to 60 cm. The stem comes out straight from the top of the short and thick rhizome, and the main root that is thick but does not split comes out from the bottom, and the end of the main root, or side root, is divided into several branches. The leaf is a compound leaf with 5 small leaves arranged in the shape of a palm, and hangs on the stem from the rhizome. One year old is 1 leaf, but 1 leaf is increased by 1 each year, and 5 to 6 leaves run after 5 to 6 years, which is the harvest season. Three years after buds appear, light green flowers bloom in groups in April-May in an umbel formed at the top of the stem. There are 5 sepals, petals and stamens each, and the stigma is divided into 2 parts.

In this specification, "extract" includes all substances obtained by extracting components of natural substances, regardless of extraction method, extraction solvent, extracted component or extract form, and also includes substances obtained by extracting components of natural substances after extraction. It is a broad concept that includes all materials that can be obtained by processing or processing by other methods, and specifically, the processing or processing may be additionally fermenting or enzymatically treating the extract. Therefore, in the present specification, extract is a broad concept including fermented product, concentrate, and dried product.

For example, the ginseng extract may be obtained by adding water or alcohol to dried ginseng (eg, 3 L), extracting at room temperature or under reflux, filtering, and then concentrating under reduced pressure at 40 to 45 ° C. The concentration of the alcohol may be 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more or 90% or more. The organic solvent may be an organic solvent having low polarity, and may include, for example, hexane, methylene chloride, ethyl acetate, and butanol. Therefore, the ginseng extract may be a soluble fraction of the organic solvent extracted with the organic solvent having low polarity.

In one aspect of the present invention, in the composition for preventing or improving hair loss or promoting hair growth, the ginsenoside F5 may be included in an amount of 0.1 ppm (w/w) to 10% (w/w) based on the total weight of the composition. there is. For example, the ginsenoside F5 is present in an amount of 0.1 ppm or more, 1 ppm or more, 3 ppm or more, 5 ppm or more, 7 ppm or more, 9 ppm or more, 10 ppm or more, 100 ppm or more, 300 ppm or more, 500 ppm or more, 700 ppm or more, 900 ppm or more, based on the total weight of the composition. or more, 1000 ppm or more, 3000 ppm or more, 5000 ppm or more, 7000 ppm or more, 9000 ppm or more, 10000 ppm or more, 30000 ppm or more, 50000 ppm or more, 70000 ppm or more, 90000 ppm or more, or 100000 ppm or more, 10% (w/w) Below, 8 % (w/w) or less, 6% (w/w) or less, 4% (w/w) or less, 2% (w/w) or less, 1% (w/w) or less, 0.1% (w/w) or less ) or less, 0.01% (w / w) or less, 0.001% (w / w) or less, or 0.00001% (w / w) or less. In addition, in terms of the above, 0.1 to 1000ppm (w / w), 1 to 1000ppm (w / w), 1 to 100ppm (w / w), 5 to 50ppm (w / w), 7 to 20ppm (w / w) w), 8 to 15 ppm (w/w), or 8 to 12 ppm (w/w), but is not limited thereto. For example, when ginsenoside F5 is included in an amount of 1 to 1000 ppm (w/w), an effect of improving hair loss or promoting hair growth may be excellent.

In the above aspect, the composition may be a pharmaceutical composition. The pharmaceutical composition according to one aspect of the present invention may be in various oral or parenteral formulations. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, soft or hard capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, and sucrose in one or more compounds. Alternatively, it is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.

In one aspect of the present invention, the pharmaceutical dosage form of the composition may be used in the form of a pharmaceutically acceptable salt thereof, and may also be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set. The salt is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, and methanesulfonic acid. , benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid and the like can be used.

In one aspect of the present invention, the composition can be administered parenterally or orally as desired, and is administered in an amount of 0.1 to 500 mg per 1 kg of body weight per day, preferably 1 to 100 mg, 1 to several times. It can be divided into doses. The dosage for a specific patient may vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of the disease, and the like.

The pharmaceutical composition according to one aspect of the present invention, according to a conventional method, oral formulations such as powders, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, aerosols, external skin preparations such as ointments and creams, It may be formulated and used in any form suitable for pharmaceutical preparations, including suppositories, injections, and sterile injection solutions, etc., and may be preferably formulated and used in the form of injections or external skin preparations.

The composition according to one aspect of the present invention can be administered to mammals such as rats, mice, livestock, and humans through various routes such as parenteral and oral, and all methods of administration can be expected, for example, It can be administered orally, transdermally, intravenously, intramuscularly, or subcutaneously.

The composition according to one aspect of the present invention may be administered through various routes that can be easily applied by those skilled in the art. In particular, the pharmaceutical composition according to one aspect of the present invention may be administered through a route applied to the skin surface as a skin external agent.

In addition, the composition may be a cosmetic composition. Specifically, the cosmetic composition may include, for example, hair cosmetics, body cosmetics, basic cosmetics, makeup cosmetics, and the like, and the formulation is not particularly limited and may be appropriately selected according to the purpose.

For example, the cosmetic composition is formulated into a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, etc. It may be, but is not limited thereto. More specifically, detergents such as shampoo, conditioner, and body cleanser, hair tonics, hair styling agents such as gels or mousses, cosmetic compositions for hair such as hair growth agents or hair dyes, softening lotions, nutrient lotions, lotions, body lotions, nutrient creams, Basic cosmetics such as massage cream, moisture cream, hand cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, gel, patch, oil-in-water (O/W) type, water-in-oil (O/W) type can be formulated as

The cosmetic composition contains a cosmetically acceptable medium or base. These are all formulations suitable for topical application, for example solutions, gels, solid or pasty anhydrous products, emulsions obtained by dispersing an oily phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and/or It may be provided in the form of a non-ionic follicular dispersant, or in the form of a cream, toner, lotion, powder, ointment, spray or conceal stick. These compositions can be prepared according to conventional methods in the art.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.

When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.

In one embodiment of the present invention, a thickening agent may be additionally contained in the cosmetic composition. The thickening agent included in the cosmetic composition of the present invention is methyl cellulose, carboxy methyl cellulose, carboxy methyl hydroxyguanine, hydroxy methyl cellulose, hydroxyethyl cellulose, carboxy vinyl polymer, polyquaternium, cetearyl alcohol, stearic acid, Carrageenan and the like may be used, preferably at least one of carboxy methyl cellulose, carboxy vinyl polymer, and polyquaternium may be used, and most preferably carboxy vinyl polymer.

In one embodiment of the present invention, the cosmetic composition may contain various appropriate bases and additives as needed, and the types and amounts of these components may be easily selected by the inventor. Acceptable additives may be included as needed, and for example, components such as preservatives, pigments, and additives common in the art may be further included.

The preservative may specifically be phenoxyethanol or 1,2-hexanediol, and the fragrance may be artificial fragrance.

And, in one embodiment of the present invention, the cosmetic composition may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts. Other ingredients that may be added include fats and oils, humectants, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, A blood circulation accelerator, a cooling agent, an antiperspirant, purified water, etc. are mentioned.

In addition, the blending components that may be added other than these are not limited thereto, and any of the above components can be blended within a range not impairing the objects and effects of the present invention.

In addition, in the above aspect, the composition may be a health food composition. The formulation of the food composition according to one aspect of the present invention is not particularly limited, but may be formulated into, for example, tablets, granules, powders, liquids such as drinks, caramels, gels, bars, and the like. The food composition of each formulation can be selected and blended without difficulty by those skilled in the art according to the formulation or purpose of use other than the active ingredient, and synergistic effects can occur when applied simultaneously with other ingredients.

In the food composition according to one aspect of the present invention, the dosage determination of the active ingredient is within the level of those skilled in the art, and its daily dosage is, for example, 0.1 mg/kg/day to 5000 mg/kg/day, more specifically It may be 50 mg/kg/day to 500 mg/kg/day, but is not limited thereto, and may vary depending on various factors such as the age, health condition, and complications of the subject to be administered.

The food composition according to one aspect of the present invention is, for example, various foods such as chewing gum, caramel products, candies, frozen confectionery, and confectionery, beverage products such as soft drinks, mineral water, and alcoholic beverages, and health products including vitamins and minerals. It may be functional foods.

In addition to the above, in one aspect of the present invention, the food composition is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like. In addition, in one aspect of the present invention, functional food compositions may include natural fruit juice and fruit flesh for preparing fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not so critical, but in one aspect of the present invention, it is generally included in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition.

Hereinafter, the present invention will be described in more detail with reference to the following Examples and Experimental Examples. However, these examples and experimental examples are provided only for illustrative purposes to aid understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Preparation of dermal papilla cells

Human dermal papilla cells (hDPs, C-12071) were purchased from Promocell (GmbH, Heidelberg, Germany). Human dermal papilla cells were cultured in a culture medium (Follicle Dermal Papilla Cell Growth Medium Kit (C-26502)) purchased from Promocells under conditions of 37° C. and 5% CO 2 in an incubator. Dermal papilla cells were cultured three times (Yoon SY et al., A role of placental growth factor in hair growth, Dermatol. Sci. 2014).

[Example 2] Confirmation of the effect of ginsenoside F5 on promoting placental growth factor expression

3X104 subcultured dermal papilla cells obtained in Example 1 were dispensed into a 35 mm culture dish, and substances expected to have an effect on improving hair loss (epigallocatechin (EGC), epigallocatechin gallate (EGCG), Green tea stem cell extract (GT stem cells), ginsenoside F1, ginsenoside F2, ginsenoside F5, ginsenoside compound K) were treated at 10 ppm (w/w) each and cultured for 24 hours. , The expression level of placental growth factor was measured. The above materials were purchased from Nanjing Chemlin Chemical Industry Co.

The expression level of placental growth factor (PIGF) was measured using an immunoenzyme measurement kit (Raybiotech, Cat. No. ELH-PLGF) according to the kit manufacturer's protocol. Specifically, in order to prepare a standard curve, PIGF (1,000 pg/ml, 333.3 pg/ml, 111.1 pg/ml, 37.04 pg/ml, 12.35 pg/ml, 4.125 pg/ml, 1.372 pg/ml, 0 pg/ml,) and each of the culture solutions (200 μl) treated with the candidate materials were put into a 96-well plate coated with PIGF antibody. After washing three times with washing buffer, biotinylated anti-human PlGF antibody was added to each well and incubated for about 1 hour. Thereafter, unbound biotinylated anti-human PIGF antibody was removed by washing three times with washing buffer, and then HRP-conjugated streptavidin was added to each well and incubated for 45 minutes. After that, after washing three times with the washing buffer, 3,3,5,5-tetramethylbenzidine (TMB) was added, and after waiting for the color reaction for 30 minutes, the reaction After stopping the chemical reaction of each well by adding a stop solution, the measurement was performed at 450 nm in a spectrophotometer. After preparing a standard curve based on the concentration value of standard PlGF (standard PlGF) and the OD (optical density) value measured in a spectrophotometer, the OD value of the sample treated with each candidate material was substituted, and the The increased expression level of PlGF was calculated. As a result, when ginsenoside F5 was treated, it was found that the expression level of PlGF was increased by 50% or more compared to the negative control group (FIG. 1).

Formulation examples of the composition according to one aspect of the present invention will be described below, but can also be applied to various other formulations, which are only intended to be specifically described and not intended to limit the present invention.

[Formulation Example 1] Soft capsule

0.004 mg of ginsenoside F5, 9 mg of vitamin E, 9 mg of vitamin C, 2 mg of palm oil, 8 mg of hydrogenated vegetable oil, 4 mg of yellow wax, and 9 mg of lecithin were mixed and mixed according to a conventional method to prepare a soft capsule filling solution. Soft capsules are prepared by filling 400 mg per capsule. In addition to the above, soft capsule sheets containing 400 mg of the composition according to one aspect of the present invention were prepared by preparing a soft capsule sheet at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerin, and 10 parts by weight of sorbitol solution, and filling the filling solution. do.

[Formulation Example 2] Tablets

0.005 mg of ginsenoside F5, 9 mg of vitamin E, 9 mg of vitamin C, 200 mg of galacto-oligosaccharide, 60 mg of lactose, and 140 mg of maltose of Example 1 were mixed and granulated using a fluidized bed dryer, followed by sugar ester 6 add mg. Tablets were prepared by compressing 500 mg of these compositions in a conventional manner.

[Formulation Example 3] Health functional food

According to the composition shown in Table 1 below, health functional foods were prepared in a conventional manner.

formulation content Ginsenoside F5 30 μg Vitamin A Acetate 70 μg vitamin E 1.0mg vitamin B1 0.13mg vitamin B2 0.15mg vitamin B6 0.5mg vitamin B12 0.2 μg vitamin C 10mg biotin 10 μg nicotinic acid amide 1.7mg folic acid 50 μg Calcium Pantothenate 0.5mg ferrous sulfate 1.75mg zinc oxide 0.82mg magnesium carbonate 25.3mg Potassium Phosphate Monobasic 15mg Dibasic Calcium Phosphate 55 mg potassium citrate 90 mg calcium carbonate 100mg magnesium chloride 24.8mg

Although the composition ratio of the above vitamin and mineral mixture is a mixture of ingredients suitable for a relatively health functional food in a preferred embodiment, the mixing ratio may be arbitrarily modified.

[Formulation Example 4] Health drink

A health drink was prepared in a conventional manner according to the composition shown in Table 2 below.

formulation content Ginsenoside F5 200mg citric acid 1000mg oligosaccharide 100 grams taurine 1g Purified water balance

After mixing the above components according to a conventional health drink manufacturing method, stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered and sterilized.

[Formulation Example 5] Shampoo

Shampoo was prepared by a conventional method according to the composition shown in Table 3 below.

formulation Content (% by weight) Ginsenoside F5 0.001 Ammonium Laureth Sulfate 10.0 Glycol Distearate 2.0 cetyl alcohol 0.6 Cocamide MEA 0.5 Ammonium Lauryl Sulfate 6.0 Guar Hydroxypropyltrimonium Chloride 0.15 Polyquaternium-10 0.1 silicon 0.5 distearyldimethylammonium chloride 0.2 Sodium Cocoamphoacetate 4.0 Spices 1.0 antiseptic 0.03 citric acid Appropriate amount Purified water balance

[Formulation Example 6] Rinse

A rinse was prepared in a conventional manner according to the composition shown in Table 4 below.

formulation Content (% by weight) Ginsenoside F5 0.001 cetyl alcohol 3.0 Glycerin monostearate 1.0 Hydroxyethyl Cellulose 1.0 propylene glycol 4.0 Methyl parahydroxybenzoate 0.2 Stearyldimethylbenzylammonium chloride 25% 10.0 Spices Appropriate amount pigment Appropriate amount citric acid Appropriate amount Purified water balance

[Formulation Example 7] Ointment

An ointment was prepared in a conventional manner according to the composition shown in Table 5 below.

formulation Content (% by weight) Ginsenoside F5 0.001 Butylene Glycol 4.0 liquid paraffin 15.0 beta glucan 7.0 carbomer 0.1 Caprylic/Capric Triglyceride 3.0 squalane 1.0 Cetearyl Glucoside 1.5 Sorbitan Stearate 0.4 cetearyl alcohol 1.0 beeswax 4.0 glycerin 8.0 Preservatives, Colors, Flavors Appropriate amount Purified water balance

[Formulation Example 8] Massage Cream

Massage cream was prepared in a conventional manner according to the composition shown in Table 6 below.

formulation Content (% by weight) Ginsenoside F5 0.001 glycerin 8.0 Butylene Glycol 4.0 liquid paraffin 45.0 beta glucan 7.0 carbomer 0.1 Caprylic/Capric Triglyceride 3.0 beeswax 4.0 Cetearyl Glucoside 1.5 Sesquioleate Sorbitan 0.9 Vaseline 3.0 paraffin 1.5 Preservatives, Colors, Flavors Appropriate amount Purified water balance

[Formulation Example 9] Hair pack

According to the composition shown in Table 7 below, a hair pack was prepared by a conventional method.

formulation ingredients Content (% by weight) Ginsenoside F5 0.001 glycerin 4.0 polyvinyl alcohol 15.0 hyaluronic acid extract 5.0 beta glucan 7.0 allantoin 0.1 nonyl phenyl ether 0.4 Polysorbate 60 1.2 ethanol preservative 6.0 Preservatives, Colors, Flavors Appropriate amount Purified water balance

[Formulation Example 10] Injection

Injections were prepared by a conventional method according to the composition shown in Table 8 below.

formulation content Ginsenoside F5 0.01-0.05 mg Sterile Distilled Water for Injection Appropriate amount pH modifier Appropriate amount

Having described specific parts of the present invention in detail above, it is clear that these specific techniques are only preferred embodiments for those skilled in the art, and the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims (7)

A composition for preventing or improving hair loss or promoting hair growth, comprising ginsenoside F5, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient. According to claim 1,
The composition promotes the secretion of growth factors in scalp cells, preventing or improving hair loss, or a composition for promoting hair growth. According to claim 2,
The scalp cells are dermal papilla cells, preventing or improving hair loss, or a composition for promoting hair growth. According to claim 2,
The growth factor is a placental growth factor, preventing or improving hair loss, or a composition for promoting hair growth. According to claim 1,
The ginsenoside F5 is a composition for preventing or improving hair loss derived from ginseng, or promoting hair growth. According to claim 1,
The ginsenoside F5,
0.1 ppm (w / w) to 10% (w / w) based on the total weight of the composition, hair loss prevention or improvement, or a composition for promoting hair growth. According to claim 1,
The composition is
A pharmaceutical composition, a cosmetic composition, or a health food composition, preventing or improving hair loss, or a composition for promoting hair growth.